Dublin, April 08, 2020 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Pulmonary Arterial Hypertension in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
Pulmonary Arterial Hypertension Disease Understanding
Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hypertension which is characterized by the elevated pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) in blood vessels carrying the blood from the right side of the heart through lungs. It occurs due to the tightening and stiffening of the small pulmonary arteries leading to the right ventricular dysfunction and vessel obstruction.
Pulmonary Arterial Hypertension Epidemiology
The Pulmonary Arterial Hypertension epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Pulmonary Arterial Hypertension are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Pulmonary Arterial Hypertension Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population of PAH, subtype-specific population of PAH and gender-specific PAH diagnosed pool) scenario of Pulmonary Arterial Hypertension in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.
Report Scope
- The report covers detailed overview of Pulmonary Arterial Hypertension explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The report provides the insight about the historical and forecasted patient pool of Pulmonary Arterial Hypertension in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan.
- The Report assesses the disease risk and burden and highlights the unmet needs of the disease
- The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
- The report provides the segmentation of the disease total prevalent population of PAH, subtype-specific population of PAH and gender-specific PAH diagnosed pool in 7MM
Key Topics Covered:
1. Key Insights
2. Executive Summary of Pulmonary Arterial Hypertension
3. SWOT Analysis for Pulmonary Arterial Hypertension
4. Pulmonary Arterial Hypertension (PAH) Epidemiology Overview at a Glance
4.1. Patient Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2017
4.2. Patient Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2030
5. Disease Background and Overview: Pulmonary Arterial Hypertension (PAH)
5.1. Introduction
5.2. Signs and Symptoms
5.3. Classification of Pulmonary Arterial Hypertension (PAH)
5.3.1. WHO classification
5.3.2. Functional Classification of PAH
5.4. Etiology
5.5. Risk factors
5.6. Pathophysiology
5.7. Diagnosis
5.7.1. Diagnostic Guidelines: European Guidelines of PAH
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Population and Forecast Parameters
6.3. 7MM Total Prevalent Patient Population of Pulmonary Arterial Hypertension [PAH]
7. Country Wise-Epidemiology of Pulmonary Arterial Hypertension (PAH)
7.1. The United States
7.1.1. Total Prevalent Patient Population of PAH in the United States
7.1.2. Sub-type Specific Prevalence of PAH in the United States
7.1.3. Gender specific Prevalence of PAH in the United States
7.2. Germany
7.2.1. Total Prevalent Patient Population of PAH in Germany
7.2.2. Sub-type Specific Prevalence of PAH in Germany
7.2.3. Gender specific Prevalence of PAH in Germany
7.3. France
7.3.1. Total Prevalent Patient Population of PAH in France
7.3.2. Sub-type Specific Prevalence of PAH in France
7.3.3. Gender specific Prevalence of PAH in France
7.4. Italy
7.4.1. Total Prevalent Patient Population of PAH in Italy
7.4.2. Sub-type Specific Prevalence of PAH in Italy
7.4.3. Gender specific Prevalence of PAH in Italy
7.5. Spain
7.5.1. Total Prevalent Patient Population of PAH in Spain
7.5.2. Sub-type Specific Prevalence of PAH in Spain
7.5.3. Gender specific Prevalence of PAH in Spain
7.6. The United Kingdom
7.6.1. Total Prevalent Patient Population of PAH in the UK
7.6.2. Sub-type Specific Prevalence of PAH in the UK
7.6.3. Gender specific Prevalence of PAH in the United Kingdom
7.7. Japan
7.7.1. Total Prevalent Patient Population of PAH in Japan
7.7.2. Sub-type Specific Prevalence of PAH in Japan
7.7.3. Gender specific Prevalence of PAH in Japan
8. Treatment Algorithm
8.1. Current Treatment Practices
8.2. Treatment Guidelines
8.2.1. CHEST Guidelines [The United States]
8.2.2. European Society of Cardiology (ESC) and of the European Respiratory Society (ERS) Guidelines
9. Unmet Needs
10. Case Studies
10.1. A Rare Case of Drug Induced PAH
10.2. A Case Report of Unconventional Delivery of Inhaled NO
11. Organizations related with PAH
12. Appendix
12.1. Bibliography
12.2. Report Methodology
13. Capabilities
14. Disclaimer
15. About the Publisher
For more information about this report visit https://www.researchandmarkets.com/r/m2dgj
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.